SPDR S&P Biotech ETF (XBI) Stock
Key stats
- Market cap
- $8.00B
- Volume
- Loading
- 52-week high
- $169.89
- 52-week low
- $106.30
Source: third-party data provider, as of November 6, 2026
Recent news

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas
SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas
XBI

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
XBI

ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings
ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings
XBI

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
XBI
Technical indicators
- RSI 14
- 43.74
- MACD 12/26/9
- -0.00
- EMA 9 of MACD
- -0.35
- MACD histogram
- 0.35
- SMA 50
- $155.54
- Price below SMA 50
- EMA 50
- $153.98
- Price below EMA 50
- SMA 200
- $142.20
- Price above SMA 200
- EMA 200
- $142.09
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas
SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas
XBI

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
XBI

ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings
ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings
XBI

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
XBI

CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
XBI

AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
XBI

IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heist
IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heist
XBI

SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400%
SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400%
XBI

Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
XBI

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
XBI
News tone: automated (AI) classification of the article's content, not a price prediction.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: Biotechnology.
Fundamentals
Trading
Dividend
Source: third-party data provider, as of November 6, 2026
Technical indicators
- RSI 14
- 43.74
- MACD 12/26/9
- -0.00
- EMA 9 of MACD
- -0.35
- MACD histogram
- 0.35
- SMA 50
- $155.54
- Price below SMA 50
- EMA 50
- $153.98
- Price below EMA 50
- SMA 200
- $142.20
- Price above SMA 200
- EMA 200
- $142.09
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.9 | -0.2 | ||||||||||
| 2022 | -19.1 | -5.4 | +0.9 | -20.8 | -10.4 | +10.0 | +6.0 | +5.3 | -7.2 | +2.7 | +1.0 | -0.1 |
| 2023 | +9.0 | -7.7 | -8.3 | +4.1 | +2.3 | -2.2 | +1.6 | -4.9 | -10.0 | -6.3 | +11.7 | +14.7 |
| 2024 | -3.1 | +10.6 | -6.5 | -9.8 | +2.1 | +1.4 | +6.5 | +2.6 | +0.1 | -1.0 | +0.4 | -9.3 |
| 2025 | +1.2 | -3.0 | -5.3 | +6.1 | -4.0 | +2.1 | +3.1 | +4.6 | +7.9 | +11.2 | +12.1 | +1.7 |
| 2026 | +2.7 | +0.0 | +0.9 | +2.2 | +4.8 | +18.4 | -6.1 | +10.3 | -3.5 | +1.0 | -2.4 |
Corporate actions
Upcoming
No upcoming corporate actions for XBI




